Haverford Financial Services Inc. boosted its stake in shares of CVS Health Corp (NYSE:CVS) by 8.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,307 shares of the pharmacy operator’s stock after purchasing an additional 14,358 shares during the quarter. CVS Health accounts for approximately 4.1% of Haverford Financial Services Inc.’s holdings, making the stock its 8th biggest position. Haverford Financial Services Inc.’s holdings in CVS Health were worth $12,003,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in CVS. 1 North Wealth Services LLC bought a new stake in shares of CVS Health in the 3rd quarter worth about $29,000. Centaurus Financial Inc. lifted its position in CVS Health by 570.8% during the 1st quarter. Centaurus Financial Inc. now owns 1,630 shares of the pharmacy operator’s stock worth $30,000 after buying an additional 1,387 shares in the last quarter. Manchester Financial Inc. acquired a new position in CVS Health during the 2nd quarter worth about $31,000. Hudock Capital Group LLC lifted its position in CVS Health by 54.0% during the 2nd quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 202 shares in the last quarter. Finally, Executive Wealth Management LLC lifted its position in CVS Health by 62.4% during the 2nd quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 217 shares in the last quarter. Hedge funds and other institutional investors own 76.17% of the company’s stock.
In related news, EVP Joshua Matthew Flum sold 17,703 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $63.00, for a total transaction of $1,115,289.00. Following the completion of the sale, the executive vice president now directly owns 36,163 shares of the company’s stock, valued at approximately $2,278,269. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Troyen A. Brennan sold 23,604 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $68.00, for a total value of $1,605,072.00. Following the sale, the executive vice president now directly owns 107,921 shares of the company’s stock, valued at $7,338,628. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,437 shares of company stock valued at $3,248,811. 0.53% of the stock is owned by company insiders.
Shares of NYSE:CVS traded up $0.69 during mid-day trading on Friday, reaching $72.47. The stock had a trading volume of 9,243,125 shares, compared to its average volume of 6,966,567. The firm has a market cap of $87.55 billion, a PE ratio of 10.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.86. The firm has a 50 day simple moving average of $64.49 and a two-hundred day simple moving average of $58.44. The company has a current ratio of 0.95, a quick ratio of 0.64 and a debt-to-equity ratio of 1.39. CVS Health Corp has a twelve month low of $51.72 and a twelve month high of $82.15.
CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.07. The business had revenue of $64.81 billion for the quarter, compared to the consensus estimate of $62.99 billion. CVS Health had a net margin of 1.91% and a return on equity of 16.15%. CVS Health’s revenue for the quarter was up 36.5% on a year-over-year basis. During the same period last year, the company posted $1.73 EPS. On average, equities analysts anticipate that CVS Health Corp will post 6.99 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Monday, November 4th. Investors of record on Thursday, October 24th were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, October 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.76%. CVS Health’s payout ratio is 28.25%.
A number of research analysts have issued reports on CVS shares. UBS Group restated a “buy” rating and set a $78.00 target price on shares of CVS Health in a research report on Thursday. Raymond James upped their target price on shares of CVS Health from $75.00 to $80.00 and gave the company a “strong-buy” rating in a research report on Thursday. Bank of America upped their target price on shares of CVS Health from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. Mizuho upped their target price on shares of CVS Health from $71.00 to $82.00 and gave the company a “buy” rating in a research report on Friday. Finally, TheStreet upgraded shares of CVS Health from a “c+” rating to a “b-” rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $78.17.
About CVS Health
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Read More: What is the Current Ratio?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.